Skip to main content
. 2016 Dec;6(4):498–507. doi: 10.1086/688489

Table 1.

Patient characteristics

Characteristic Controls
(n = 31)
Portopulmonary hypertension
(n = 21)
P
Age, years 58.0 (50.0–65.0) 55.0 (48.0–63.0) NS
Female sex 9 (29.0) 5 (23.8) NS
Race/ethnicity NS
 White 25 (80.6) 15 (71.4)
 Hispanic/Latino 4 (12.9) 4 (19)
 Black 2 (6.5) 2 (9.5)
 Other 0 2 (9.5)
Comorbidities NS
Hypertension 17 (54.8) 10 (47.6)
Diabetes mellitus 16 (51.6) 10 (47.6)
ESRD with hemodialysis 3 (9.7) 1 (4.8)
HCC 5 (16.1) 4 (19.0)
Systemic glucocorticoid use 3 (9.7) 1 (5.3) (n = 19)
Etiology of liver disease NS
 Alcohol 15 (48.4) 11 (52.4)
 HCV infection 9 (29.0) 8 (38.1)
 HCV infection plus alcohol 1 (3.2) 4 (19.0)
 Nonalcoholic fatty liver disease 4 (12.9) 1 (4.8)
 Autoimmune 0 1 (4.8)
 Other 9 (29.0) 4 (23.8)
Liver disease severity
 MELD 17 (12–24) 11 (9–14) 0.002
 Child class <0.001
  A 2 (6.5) 9 (42.9)
  B 13 (41.9) 11 (52.4)
  C 16 (51.6) 1 (4.8)
Physical examination
 Body mass index 28.6 (25.6–32.3) (n = 27) 29.1 (23.7–35.0) (n = 16) NS
 Oxygen saturation 97 (95.5–99.0) (n = 29) 96 (95–98) (n = 18) NS
Tricuspid regurgitation gradient by echocardiogram, mmHg 37 (35–45) (n = 26) 53 (42–68) (n = 20) 0.002
Hemodynamic characteristics
 mPAP, mmHg 24 (19–30) 38 (31–48) <0.001
 PAWP, mmHg 15.5 (11.5–20) 10 (5.5–13.5) <0.001
 PVR, dynes˙s˙cm−5 86.4 (50.4–119.0) 327.7 (267.0–534.9) <0.001
 CO, L/min 7.7 (6.7–10.3) 6.3 (5.3–7.6) 0.001
Note

Patients may have had more than one listed race/ethnicity, diagnosis, or comorbidity. Data are expressed as median (interquartile range) or number (%). CO: cardiac output; ESRD: end-stage renal disease; HCC: hepatocellular carcinoma; HCV: hepatitis C virus; MELD: model for end-stage liver disease; mPAP: mean pulmonary arterial pressure; NS: not significant; PAWP: pulmonary arterial wedge pressure; PVR: pulmonary vascular resistance.